Evaluation of in silico splice tools for decision‐making in molecular diagnosis

It appears that all types of genomic nucleotide variations can be deleterious by affecting normal pre‐mRNA splicing via disruption/creation of splice site consensus sequences. As it is neither pertinent nor realistic to perform functional testing for all of these variants, it is important to identify those that could lead to a splice defect in order to restrict transcript analyses to the most appropriate cases. Web‐based tools designed to provide such predictions are available. We evaluated the performance of six of these tools (Splice Site Prediction by Neural Network [NNSplice], Splice‐Site Finder [SSF], MaxEntScan [MES], Automated Splice‐Site Analyses [ASSA], Exonic Splicing Enhancer [ESE] Finder, and Relative Enhancer and Silencer Classification by Unanimous Enrichment [RESCUE]‐ESE) using 39 unrelated retinoblastoma patients carrying different RB1 variants (31 intronic and eight exonic). These 39 patients were screened for abnormal splicing using puromycin‐treated cell lines and the results were compared to the predictions. As expected, 17 variants impacting canonical AG/GT splice sites were correctly predicted as deleterious. A total of 22 variations occurring at loosely defined positions (±60 nucleotides from an AG/GT site) led to a splice defect in 19 cases and 16 of them were classified as deleterious by at least one tool (84% sensitivity). In other words, three variants escaped in silico detection and the remaining three were correctly predicted as neutral. Overall our results suggest that a combination of complementary in silico tools is necessary to guide molecular geneticists (balance between the time and cost required by RNA analysis and the risk of missing a deleterious mutation) because the weaknesses of one in silico tool may be overcome by the results of another tool. Hum Mutat 29(7), 975–982, 2008. © 2008 Wiley‐Liss, Inc.

[1]  C. Amos,et al.  Missense mutations in hMLH1 and hMSH2 are associated with exonic splicing enhancers. , 2003, American journal of human genetics.

[2]  A. Krainer,et al.  Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5′ splice‐site disruption , 2007, Human mutation.

[3]  L. Desjardins,et al.  Genotype–phenotype correlations in hereditary familial retinoblastoma , 2007, Human mutation.

[4]  A. Krainer,et al.  Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1 , 2004, Human mutation.

[5]  Peidong Shen,et al.  Conservation of the RB1 gene in human and primates , 2005, Human mutation.

[6]  T. D. Schneider,et al.  Information analysis of human splice site mutations , 1998, Human mutation.

[7]  A. Krainer,et al.  Pre-mRNA splicing in the new millennium. , 2001, Current opinion in cell biology.

[8]  David Haussler,et al.  Improved splice site detection in Genie , 1997, RECOMB '97.

[9]  Andrew P. Bradley,et al.  The use of the area under the ROC curve in the evaluation of machine learning algorithms , 1997, Pattern Recognit..

[10]  G. Cutting,et al.  A variable dinucleotide repeat in the CFTR gene contributes to phenotype diversity by forming RNA secondary structures that alter splicing. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Guanti,et al.  In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects , 2006, BMC Genomics.

[12]  L. Desjardins,et al.  A deep intronic mutation in the RB1 gene leads to intronic sequence exonisation , 2007, European Journal of Human Genetics.

[13]  D. Frappaz,et al.  A T to C mutation in the polypyrimidine tract of the exon 9 splicing site of the RB1 gene responsible for low penetrance hereditary retinoblastoma , 2002, Journal of medical genetics.

[14]  Jinhua Wang,et al.  ESEfinder: a web resource to identify exonic splicing enhancers , 2003, Nucleic Acids Res..

[15]  Christopher B. Burge,et al.  Maximum Entropy Modeling of Short Sequence Motifs with Applications to RNA Splicing Signals , 2004, J. Comput. Biol..

[16]  Phillip A Sharp,et al.  Predictive Identification of Exonic Splicing Enhancers in Human Genes , 2002, Science.

[17]  L. Desjardins,et al.  Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF , 2004, Human mutation.

[18]  Peter K Rogan,et al.  Automated splicing mutation analysis by information theory , 2005, Human mutation.

[19]  Sean V Tavtigian,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Chasin,et al.  Multiple Splicing Defects in an Intronic False Exon , 2000, Molecular and Cellular Biology.

[21]  Marvin B. Shapiro,et al.  RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. , 1987, Nucleic acids research.

[22]  T. Cooper,et al.  The regulation of splice-site selection, and its role in human disease. , 1997, American journal of human genetics.

[23]  A. Krainer,et al.  Listening to silence and understanding nonsense: exonic mutations that affect splicing , 2002, Nature Reviews Genetics.

[24]  W. Henn,et al.  Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants , 2006, Human Genetics.

[25]  J. Hampe,et al.  Single base‐pair substitutions in exon–intron junctions of human genes: nature, distribution, and consequences for mRNA splicing , 2007, Human mutation.

[26]  Thilo Dörk,et al.  Nonclassical splicing mutations in the coding and noncoding regions of the ATM Gene: Maximum entropy estimates of splice junction strengths , 2004, Human mutation.

[27]  J. Dunlevy,et al.  Nuclear and plasma membrane localization of SH3BP4 in retinal pigment epithelial cells. , 2004, Molecular vision.

[28]  R. Scott,et al.  Inhibition of nonsense-mediated messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques. , 1997, Cancer research.

[29]  T. Cooper,et al.  Finding signals that regulate alternative splicing in the post-genomic era , 2002, Genome Biology.